Admedus gains U.S. clearance for cardiovascular scaffold

Admedus lands FDA 510(k) clearance for its CardioCel, a tissue regeneration product designed to treat a range of cardiovascular and vascular defects.

Admedus won 510(k) clearance from the U.S. FDA for its CardioCel cardiovascular scaffold.

Perth, Australia and Minneapolis, Minn.-based Admedus is developing implantable regenerative technologies. CardioCel, the company's 1st product, is a pure collagen, bio-compatible regenerative tissue scaffold.

News Well, 510(k), Cardiovascular, Minnesota, Regulatory/Compliance, Vascular, Vascular Closure

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/O9NzAz